Thomas J. Langan, M.D. Department of Neurology State University of NY at Buffalo
|
|
- Amanda Rosalyn Willis
- 5 years ago
- Views:
Transcription
1 Enhancement of Newborn Screening to Improve the Efficacy of Cord Blood Transplant for Krabbe Disease Thomas J. Langan, M.D. Department of Neurology State University of NY at Buffalo
2
3 0RIG INALARTICLE Transplantation of Umbilical-Cord Blood in Babies with It1far1tile Krabbe~s Disease Maria L. Esc alar, M.ID., MicheleD. Poe, Ph.D.: James M. Provenzale: M.., Karen C. Rrehards] M.D., June All"son. R.N., Susan Wood= P.N.P. 1 David A. Wenger] Ph.D., Dan el Pietryga, M.D., Donna Wall 1 M.D. 1 ~ artin Champagne ~ M.D. ~ Richard orse, ~.0., ~NiJUam Krivit, M.D., Ph.D.; and Joanne Kurtzberg, 1.0. NEngIJ ed 20 5: 352: May 19, 2005 DOl: /NEJ 1Da0 2604
4 Kaplan Meier Estimates of the Probability of Overall Survival among Patients with Krabbe's Disease. As)mp omattc ne wborns 0.4 S} mptoma. c nfants 0.2 ~.. ~-+- r Untreated control group '-~\,...., ; ;..~ ; i! ,,--,.----,--.---,--,---,r !2 24 l6 c;o A!re (months) 108 Escolar ML et al. N Engl J Med 2005;352:
5 Long Term Follow-up of Transplanted Early Infantile Krabbe Patients (Neurol. 89: , 2017)
6 Cognitive Development After Presmyptomatic Transplantation
7 Motor Development after Transplantation
8 Survey of Living Krabbe Patients from Buffalo Registry- Objectives 1. Develop a new Quality of Life (QOL) survey to better describe the natural history, phenotypes and responses to stem cell transplantation (SCT) of Krabbe Disease (KD). 2. Assess the concurrent validity and reliability of this survey, the Leukodystrophy QOL Assessment (LQLA), by co-administering it with the Vineland, an already validated QOL survey.
9 METHODS Phone calls to living patients in WWR. N= 33 ( of 45 attempted) 11 Early Infantile KD (EIKD), 7 Late Infantile KD (LIKD), 12 late onset KD (LOKD), and 3 with genotypes indicating risk for LOKD. SCT was achieved in cases of EIKD (2 before and 2 after symptoms emerged), LIKD (1 after symptoms) and LOKD ( 3 before and 3 after symptoms).
10 Measure Quality of Life Survey: Differences Between Transplant Groups Sample of Krabbe Cases N = 30 Estimated Mean by Transplant Time Transplant ANOVA P-Value None (N = 19) Post-Symptom (N = 6) Pre-Symptom (N = 5) Overall , 2 Communication , 2 Daily Living , 2 Social , 2 Motor , 2 Duncan Grouping 1 Indicates pre-symptomatic transplant mean significantly higher than no-transplant mean 2 Indicates pre-symptomatic transplant mean significantly higher than post-symptomatic transplant mean
11 Quality of Life Survey: Phenotypic Differences Sample of Krabbe Cases N = 30 Measure Phenotype Estimated Mean by Phenotype Duncan ANOVA P- EIKD (N = 11) LIKD (N = 7) LO (N = 12) Grouping Value Overall Communication , 2 Daily Living Social Motor , 2 1 Indicates LO mean significantly higher than EIKD mean 2 Indicates LO mean significantly higher than LIKD mean 3 Indicates no significant differences between group means
12 Presymptomatic/Early Transplantation for Krabbe Disease 1. It results in significant improvement of survival, cognitive function and quality of life. 2. Survey of quality of life better defines early infantile Krabbe (speech and communication deficits predominantly distinguish phenotypes ). 2. The benefits upon cognitive function and quality of life are not observed after post-symptomatic transplantation. 3. Consequently, early diagnosis of risk for Krabbe after NBS will enhance the efficacy stem cell transplantation.
13 Psychosine Hypothesis It postulated that galactosylsphingosine (psychosine), which cannot be degraded due to the underlying genetic defect, is responsible for the very rapid loss of the oligodendrocytes and the consequent paradoxical analytical finding, the lack of accumulation of the primary substrate, galactosylceramide, in patients' brain. It took nearly ten years before the actual accumulation of psychosine was demonstrated in human Krabbe patients and also in the brain of twitcher mice, an equivalent murine mutant. From K. Suzuki, J. Neurochem Res Mar;23(3):251-9.
14 .. G lactosyl _phingo ine G 1acto ylcer nlide CJ (Psychosine),/:, H f3-9alactocerebrosidase!l Q. (Krabbe.. 0 disease).,t:, c. Q» c acid ceramidase acid sphingonlyelinase 0 phingo in~ Ceramide 0') (Farber di ease) (Niemann-Pick disease Sphingomyelin c:: -.&:. type A and B) P glucosidase (Gaucher disease) a.. (I) ll l!! ~ Glucosylsphingosine (Giucopsycho ine) Gfucosylceranlide Ly o
15 1 hthcrit lt. fcmb n 4:201. -) J 8: ~ LO. L007/s L LS-98:22-:z. ORIGINA.\l,M{11CLE lea 1rement of p,.. cho in in dried blood pot ~a po, ible impro. ement tone rbo n. creenin~ rogram. for Krabbe di. ea ~e ~Coleo1an T. Tm:geon.. Joseph J ~ Or:s In i.. Ka11en A. n den.. t\tark..1. t\1 a em.. Thoma J'"' angan tar'"~ L"' [sc,oli~r.. Patrida Duffner.. De In 0 I bee.. llimi tar ~BJvrilo.... il\l, 111:iortoreIIi.. Pi!i!rO Rin ajdo.. K imi... o Ra... n1ond.. Dj!i!hiLh I uern
16 EICLO 50D JWD 30.0 : r to.o -...J ao -: r ~ -r: B P-0..~ :::::: a.. E "-0 C:.].. - a:: J "10... ' >... _._ (!"] 2.D..:L.-.. t.o _L Fl r [.~ _L E ~ Ill.. P...ru=685 P-o.lr."SQ P-0. DB6 o.e (12 p...o_(j343 C~::J p.o:fj. 00)1 Pd:UDII1 0.1 lj, A IB c 0 IE F G H y No:rmal [:()Otro a J.. v I ll '{' J "-..,
17 J ournal of euroscience Reserdrch 94: (...016) Can Psychosine and Galactocerebrosidase Activity Predict Early-Infantile Krabbe's Disease Presymptomatically? 1.2 T- 11.1_ 2 3 K ll_'"' 1 I 1 ] 2 1 I J 0.. "' 4 R and.. L. C ar-ter~ LLil-'\ITrencc raluetz~ aluii" a a ~ oscp 1.. rsnm~ Arrty L. Barczyko ;vslci~ 1 1 Diettich Matern, 5 and hontas J. Langmn 2 "" 1 *
18
19 7.5 Bivariate Normal Limits Estimated from Wadsworth Normative Sample (N = 166) Univariate Standardization of Natural Log of Psychosinc/GALC 5.0,.-.-. >-< 2.5 r:/) ~ '-._/ 3 C1) " 0.0 N 1-. "ro " c:... ro -2.5 r:/) Standardized LN(GALC) D % Prediction Ellipse % Prediction Ellipse 99% Prediction Ellipse 95% Prediction Ellipse 50% Prediction Ellipse Nonnal Wadsworth Observations Standardized using means and standard de\iations estimated from a sample of nonual newboms with measurements from \Vadswortl1 lab in 2016(LN(GALC): Mean = 0.67, SD = 0.90; LN(PSY): Mean = -1.00, SD = 0.51)
20 Bivariate Normal Limits Estimated from Wadsworth Normative Sample (N = 166) Univariate Standardization of Natural Log ofpsychosine/galc With Group H (N = 8): EIKD Asymptomatic Cases (NBS) * Standardized LN(GALC) D % Prediction Ellipse D 99.99% Prediction Ellipse 99% Prediction Ellipse 95% Prediction Ellipse 50% Prediction Ellipse Normal Wadsworth Observations + Group H Observations Standardized using means and standard deviations eslimated from a sample of nonnal newborns with measurements from Wadswotth lab in 2016(LN(GALC): Mean = SO = 0.90; LN(PSY): Mean = -1.00, SO = 0.51) +Standardized using nonnative distribution estimated from Wadswotth!Mayo data*(ln(galc): Mean = 1.24, SO = 0.58: LN(PSY): Mean= 0.88, SO= 0.41) *See Carteret. al., 2016 JNR.
21 Bivariate Normltl Limits Estimated from Wadsworth Normative Sample (N = 166) Univariate Standardization of Natural Log ofpsychosine/galc With Group D (N =8): GALC M utation Carriers (NBS) ,.-... :>-< r:/1 p '"-" 3 '"0 (!) 0.0 -~ '"0 a '" r:/ Standardized LN(GALC) D % Prediction Ellipse D 99.99% Prediction Ellipse 99% Prediction Ellipse 95% Prediction Ellipse 50% Prediction Ellipse Normal Wadsworth Observations + Group D Observations Standardized using means and standard deviations estimated from a sample ofnormal newborns with measurements from Wadsworth lab in 2016(LN(GALC): Mean = 0.67, SD = 0.90; L (PSY): Mean = -1.00, SD = 0.5 1) +Standardized using norutative distribution estimated from Wadsworth/M.ayo data*(ln(galc): Mean = 1.24, SD = 0.58; LN(PSY): Mean = 0.88, SD = 0.41) *See Carter et. al., 2016 JNR
22 Analysis of Dried Blood Spots to Develop The BVNL Krabbe NBS Tool 1. The data set consisted of: a. 15 newborn blood spots of known Krabbe patients collected by the Buffalo Research Group. b. 8 newborn blood spots from high risk cases followed in NY State. c. 3 blood spots from 3 late infantile ( 6-48 month onset) Krabbe patients followed at UPMC obtained soon after symptoms emerged. d. 1 blood spot obtained from a UPMC patient after treatment. 2. Assays of Psychosine and Galactocerebrosidase performed at Wadsworth Laboratories, NY State Department of Health.
23 Pre-symptomatic or High Risk? Pre-symptomatic cases are defined as having low enzyme levels and predictive genotypes( e.g,. 30 kb deletion homozygous or compound heterozygous with known high risk alleles). These include siblings of known cases. High risk cases have low enzyme consistent with Krabbe, but nonpredictive genotypes ( e.g, 30 kb heterozygotes with non-pathogenic additional allele 2 of 8 cases). These include possible late onset alleles and VOUS. (6 of 8 cases). All remained free of symptoms for 2-3 years.
24 BVNL Results from Krabbe Bloodspots
25 BVNL Results from 8 Asymptomatic, High Risk NY Cases
26 Bloodspot BVNL Summary Every infant whose newborn blood spot BVNL result was in the high risk zone on the probability ellipse was destined to develop Krabbe disease in infancy or early childhood. None of the New York State high risk infants newborn bloodspot results fell within the high risk zone of the ellipse, even though 5 of 8 had PSY values that would prompt concern. 1 transplanted patient whose blood spot was obtained after treatment had a normal BVNL result.
27 Accuracy of BVNL for Krabbe Prediction
28 Advantages of BVNL Tool for Predicting Krabbe Symptoms Soon After a Positive Newborn Screen 1. The false positive rate can be controlled for example at 10-6 ; this means that if all 4 million newborns in US were screened for Krabbe each year, no more than about 1 false positive very 2.5 years. 2. The Positive Predictive Value is 98.5 %. 3. This dramatic reduction of the false positive rate should facilitate early diagnosis and enhance the efficacy of treatment.
29 BVNL Advantages 4. Costly and painful diagnostic tests- LP, MRI, NCVSmay eventually be unnecessary. 5. BVNL calculations can be performed readily on open access, inexpensive software (e.g. R program). 6. There is no need to share any patient profiles or other reference data.
30 Issues Identified by Evidence Review EIKD, The Condition: need consensus about the case definition of what constitutes Early Infantile Krabbe Disease (EIKD) Test for EIKD, Screening and Diagnosis: there is a need for additional information about the testing algorithm for EIKD. It is important to ascertain whether testing for Krabbe disease would be a stand alone test or done with multiplex testing, in part because of the cost implications Treatment for EIKD: More information is needed about the specific benefits of Hematopoietic Stem Cell Transplant (HSCT) to treat patients and what mutations would benefit most from HSCT *Text taken directly from NBSTRN.org/resources/gaps-in-research
31 Progress in Filling Krabbe Disease Gaps of Knowledge EIKD, the condition: Our recent study of natural history and long term QOL better defines phenotypic expression. Test for EIKD, screening and diagnosis: The BVNL tool is potentially an extremely accurate tool for early diagnosis, essentially eliminating false positives, and enhancing treatment outcomes. Treatment for EIKD : Benefits of pre-symptomatic transplant upon survival, cognition and QOL have recently been established.
32 Filling the gaps in knowledge about Krabbe treatment, diagnosis and phenotypes
33 Acknowledgements NYS Dept. of Health: Mayo Clinic: Duke Univ.: J.Orsini D.Matern J. Kurtzberg D.Kay C.Turgeon H. Immelt M. Caggana Univ. of Pittsburgh: Mt. Sinai: M.Escolar M. Wasserstein M.Poe P. Levy SUNY Buffalo R.Carter, A. Barczykowski, K. Jalal, L. Wrabetz, L. Feltri Funding: R-21 HD (TJL, RC, LW, AB, KJ) LDN-U54NS (TJL)
INTRODUCTION. 1.
KRABBE DISEASE INTRODUCTION Krabbe disease is a genetic defect that affects the nervous system. It is caused by the shortage (deficiency) of an enzyme called galactosylceramidase. This enzyme deficiency
More informationX-ALD Newborn Screening and Follow-up testing in USA
X-ALD Newborn Screening and Follow-up testing in USA Ann B Moser, the Hugo W. Moser Research Institute, Kennedy Krieger Institute and Johns Hopkins Univ. ALD Life Meeting, London, May 5, 2018 14:00 Dr
More informationThe role of the laboratory in diagnosing lysosomal disorders
The role of the laboratory in diagnosing lysosomal disorders Dr Guy Besley, formerly Willink Biochemical Genetics Unit, Manchester Children s Hospital, Manchester M27 4HA, UK. Lysosomal disorders What
More informationA prospective natural history study of Krabbe disease in a patient cohort with onset between 6 months and 3 years of life
Bascou et al. Orphanet Journal of Rare Diseases (2018) 13:126 https://doi.org/10.1186/s13023-018-0872-9 RESEARCH Open Access A prospective natural history study of Krabbe disease in a patient cohort with
More informationNewborn Screening for Lysosomal Storage Diseases in Missouri. Outline
Newborn Screening for Lysosomal Storage Diseases in Missouri Dr. Kathy Grange Division of Genetics and Genomic Medicine Department of Pediatrics Washington University Outline Brief overview of clinical
More informationLSD EASY AND EFFICIENT SCREENING. NeoLSD MSMS kit
EASY AND EFFICIENT LSD NeoLSD MSMS kit The first commercial IVD kit for screening of Pompe, MPS-I, Fabry, Gaucher, Niemann-Pick A/B and Krabbe disorders from a single DBS sample. A PIONEER IN EXPANDING
More information!"!#$%% &'&(!# !!!"#$%&'((#&$#) !=NLZ/'(\]Z5',Z^^I /Z5Z\/6!'2N5L2L=LZ. Every !"#$%&'#('&) !"#$%&'()*%+',%--.'/%+%)&01'2#+$3$"$%
"#$%&'()*%+',%--.'/%+%)&01'2#+$3$"$% "#$%&D+'8E%'F8"#>)$38# 4)+30'503%#0% The Hunter s Hope Foundation was established to address the acute need for information and research with respect to Krabbe disease
More informationCase Discussion The Ethics of Krabbe Newborn Screening
PUBLIC HEALTH ETHICS VOLUME 6 NUMBER 1 2013 114 128 114 Case Discussion The Ethics of Krabbe Newborn Screening Richard H. Dees, University of Rochester Jennifer M. Kwon, University of Rochester Medical
More informationDNA Day Illinois 2013 Webinar: Newborn Screening and Family Health History. Tuesday, April 16, 2013
DNA Day Illinois 2013 Webinar: Newborn Screening and Family Health History Tuesday, April 16, 2013 Objectives Recognize the importance & impact of newborn screening Describe the process of newborn screening
More informationLong Term Follow-Up Clinical Guidelines for X-linked Adrenoleukodystrophy
Long Term Follow-Up Clinical Guidelines for X-linked Adrenoleukodystrophy Gerald Raymond, M.D. Department of Pediatrics and Neurology Penn State Medical Center Hershey, PA June 20, 2018 Disclosure Information
More informationDEVELOPING A FOLLOW-UP FRAMEWORK FOR POMPE DISEASE
DEVELOPING A FOLLOW-UP FRAMEWORK FOR POMPE DISEASE Presenter: Sarah Bradley, MS, CGC Genetic Counselor, NYS Newborn Screening Program Authors: S. Bradley, D. Kronn, B. Vogel, M. Caggana, J. Orsini, K.
More informationTransplantation of Umbilical-Cord Blood in Babies with Infantile Krabbe s Disease
original article Transplantation of Umbilical-Cord Blood in Babies with Infantile Krabbe s Disease Maria L. Escolar, M.D., Michele D. Poe, Ph.D., James M. Provenzale, M.D., Karen C. Richards, M.D., June
More informationNeonatal manifestations of lysosomal storage diseases
Neonatal manifestations of lysosomal storage diseases Nadia ALhashmi MD Metabolic &genetic disorder Royal hospital 2 nd Oman international pediatric and neonatal conference 13 th -15 th April 2017 Muscat
More informationTay-Sachs disease is another example of a recessive genetic disorder. (a) Explain the meaning of the term recessive genetic disorder.
1 Cystic fibrosis and albinism are examples of recessive genetic disorders. Tay-Sachs disease is another example of a recessive genetic disorder. (a) Explain the meaning of the term recessive genetic disorder.
More informationWhat s New in Newborn Screening?
What s New in Newborn Screening? Funded by: Illinois Department of Public Health Information on Newborn Screening Newborn screening in Illinois is administered by the Illinois Department of Public Health.
More informationTITLE: Newborn Screening for Krabbe Leukodystrophy: A Review of the Clinical and Cost Effectiveness and Guidelines
TITLE: Newborn Screening for Krabbe Leukodystrophy: A Review of the Clinical and Cost Effectiveness and Guidelines DATE: 17 February 2012 CONTEXT AND POLICY ISSUES Krabbe disease belongs to a group of
More informationForm 3. Template for a full review process for a condition being considered for addition to the newborn/child screening panel
Form 3. Template for a full review process for a condition being considered for addition to the newborn/child screening panel **Note: please specify the basis for each answer and rely on published evidence
More informationWhat s New in Newborn Screening?
What s New in Newborn Screening? Funded by: Illinois Department of Public Health Information on Newborn Screening Newborn screening in Illinois is mandated and administered by the Illinois Department of
More informationNeonatal Screening for Lysosomal Storage Disorders (LSD) by Tandem Mass Spectrometry (MSMS)
Neonatal Screening for Lysosomal Storage isorders (LS) by Tandem Mass Spectrometry (MSMS) Enzo Ranieri and Samantha Stark 1 Head, Neonatal Screening Centre & Biochemical Genetics (G&MP) irectorate of Genetics
More informationMolecular Genetics and Metabolism
Molecular Genetics and Metabolism 105 (2012) 126 131 Contents lists available at SciVerse ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Krabbe disease:
More informationLab Activity Report: Mendelian Genetics - Genetic Disorders
Name Date Period Lab Activity Report: Mendelian Genetics - Genetic Disorders Background: Sometimes genetic disorders are caused by mutations to normal genes. When the mutation has been in the population
More informationUK National Screening Committee. Gaucher Disease Screening in Newborn. 26 November 2014
UK National Screening Committee Gaucher Disease Screening in Newborn 26 November 2014 Aim 1. This document provides background on the item addressing Gaucher disease. Current policy 2. This is the first
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name OMIM number for disease 231300 Disease alternative names Please provide any alternative
More informationHunter s Hope Foundation
Hunter s Hope Foundation 2010 Annual Report Dear Family and Friends, The Kelly Family has been on a very unique journey this year. With the September national book release of our memoir, Without a Word
More informationDevelopment of a Multiplex CYP21A2 Genotyping Assay for Congenital Adrenal Hyperplasia Screening
Development of a Multiplex CYP21A2 Genotyping Assay for Congenital Adrenal Hyperplasia Screening Christopher N. Greene, Ph.D. Newborn Screening and Molecular Biology Branch National Center for Environmental
More informationCHAPTER 10 BLOOD GROUPS: ABO AND Rh
CHAPTER 10 BLOOD GROUPS: ABO AND Rh The success of human blood transfusions requires compatibility for the two major blood group antigen systems, namely ABO and Rh. The ABO system is defined by two red
More informationMetabolic Liver Disease
Metabolic Liver Disease Peter Eichenseer, MD No relationships to disclose. Outline Overview Alpha-1 antitrypsin deficiency Wilson s disease Hereditary hemochromatosis Pathophysiology Clinical features
More informationStatus of Newborn Screening for Lysosomal Storage Disorders in Wisconsin
Status of Newborn Screening for Lysosomal Storage Disorders in Wisconsin Technical Workshop on Methods to Detect Pompe Disease and other Lysosomal Storage Disorders (LSDs) by Newborn Bloodspot Screening
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: nusinersen_spinraza 03/2017 10/2017 10/2018 10/2017 Description of Procedure or Service Spinal muscular atrophy
More informationNewborn Screening Top 10 Challenges
Newborn Screening Top 10 Challenges Celia Kaye, MD, PhD, FAAP Robert A. Saul, MD, FAAP Newborn Screen Positive Infant ACTion Project Learning Session May 21-22, 2010 I have no relevant financial relationships
More informationNewborn screening for biotinidase deficiency
Newborn screening for biotinidase deficiency External review against programme appraisal criteria for the UK National Screening Committee (UK NSC) Version: 1 Bazian Ltd August 2012 The UK NSC advises Ministers
More informationWISKOTT-ALDRICH SYNDROME. An X-linked Primary Immunodeficiency
WISKOTT-ALDRICH SYNDROME An X-linked Primary Immunodeficiency WHAT IS WISKOTT ALDRICH SYNDROME? Wiskott-Aldrich Syndrome (WAS) is a serious medical condition that causes problems both with the immune system
More informationDiagnosis of alpha1-antitrypsin deficiency
Malmö 19-20 november 2008 Diagnosis of alpha1-antitrypsin deficiency Maurizio Luisetti Center for Diagnosis of AATD IRCCS San Matteo Hospital Foundation University of Pavia - Italy Clinical Recognition
More informationAmy Powers (N) Michael Pryor
Newborn Screening Advisory Committee Meeting Meeting Minutes of Tuesday, October 13, 2015 12:00-3:00 Wilder Center Auditorium A - D 451 Lexington Parkway North Saint Paul, MN 55104 Committee Members Present:
More informationAssociation of motor milestones and SMN2 copy and outcome in spinal muscular. atrophy types 0 4
jnnp-2016-314292 1 - SUPPLEMENTARY FILE - Methods and additional data on clinical characteristics and motor development Association of motor milestones and SMN2 copy and outcome in spinal muscular atrophy
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Leber congenital amaurosis OMIM number for disease 204000 Disease alternative
More informationIdentification of Newborn Infants at Risk for a Lysosomal Storage Disease by Tandem MS/MS
Identification of ewborn Infants at Risk for a Lysosomal Storage Disease by Tandem MS/MS C.Ronald Scott 1, 1.A collaborative project between the Univ.Washington, Washington State ewborn screening laboratory,
More informationNewborn Screening for Severe Combined Immunodeficiency (SCID) by Quantifying T-cell Receptor Excision Circles (TREC)
Newborn Screening for Severe Combined Immunodeficiency (SCID) by Quantifying T-cell Receptor Excision Circles (TREC) Patricia R. Slev, PhD, D(ABCC) Medical Director, Serologic Hepatitis and Retrovirus
More informationTesting for Genetic Disorders that Cause Brain Damage
STO-132 Testing for Genetic Disorders that Cause Brain Damage Part 1: Newborn Screening Tests Matt is watching his twins, Anna and Cody, in the newborn nursery. The nurse pokes the babies heels, collects
More informationGENOTYPE-PHENOTYPE CORRELATIONS IN GALACTOSEMIA COMPLICATIONS COMPLICATIONS COMPLICATIONS LONG-TERM CHRONIC COMPLICATIONS WITH NO CLEAR CAUSE
Galactosemia Deficiency: galactose-1-phosphate-uridyltransferase(galt) GENOTYPE-PHENOTYPE CORRELATIONS IN GALACTOSEMIA GALT D-galactose-1-phosphate UDPgalactose + + UDPglucose D-glucose-1-phosphate DIVISION
More informationboratory Testing for Chronic Granulomatous Disease: Challenges and Recommendations - Take Home Points 3/20/2017
1 The take-home points to consider for diagnostic testing for CGD: CGD is a complex and heterogeneous disease due to mutations in 1 of the components of the NADPH oxidase pathway. Functional assessment
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing
More informationStem-Cell Transplantation for Inherited Metabolic Disorders
Medical Coverage Policy Effective Date... 8/15/2017 Next Review Date... 8/15/2018 Coverage Policy Number... 0386 Stem-Cell Transplantation for Inherited Metabolic Disorders Table of Contents Related Coverage
More informationX-ALD 101: Clinical Aspects and Screening Methods
X-ALD 101: Clinical Aspects and Screening Methods April 20, 2016 Transcript Laura Russell: Patricia Hunt: Hi everyone. This is Laura Russell from APHL. We're going to go ahead and get started. I d like
More information2012 Annual Report. The Legacy of Angels Foundation is a private family 501 (c) (3) organization co-founded by Paul and Sue Rosenau in 2008.
2012 Annual Report The Legacy of Angels Foundation is a private family 501 (c) (3) organization co-founded by Paul and Sue Rosenau in 2008. To find out more about The Legacy of Angels Foundation go to:
More informationChapter 26. Newborn Screening
Chapter 26 Newborn Screening Severe Combined Immune Deficiency (SCID) leads to life-threatening infections unless the immune system can be restored through a bone marrow transplant, enzyme replacement
More informationSingle Gene (Monogenic) Disorders. Mendelian Inheritance: Definitions. Mendelian Inheritance: Definitions
Single Gene (Monogenic) Disorders Mendelian Inheritance: Definitions A genetic locus is a specific position or location on a chromosome. Frequently, locus is used to refer to a specific gene. Alleles are
More informationBIOL2005 WORKSHEET 2008
BIOL2005 WORKSHEET 2008 Answer all 6 questions in the space provided using additional sheets where necessary. Hand your completed answers in to the Biology office by 3 p.m. Friday 8th February. 1. Your
More informationALD database, diagnostic dilemmas and the need for translational metabolism
ALD database, diagnostic dilemmas and the need for translational metabolism Stephan Kemp, Ph.D. Associate Professor & AMC Principal Investigator Genetic Metabolic Diseases & Pediatrics Academic Medical
More informationMultiple Copy Number Variations in a Patient with Developmental Delay ASCLS- March 31, 2016
Multiple Copy Number Variations in a Patient with Developmental Delay ASCLS- March 31, 2016 Marwan Tayeh, PhD, FACMG Director, MMGL Molecular Genetics Assistant Professor of Pediatrics Department of Pediatrics
More informationGive Birth to Hope: An Unique Approach to Public Cord Blood Donation
Give Birth to Hope: An Unique Approach to Public Cord Blood Donation The Public Health Nursing and Professional Development Unit, North Carolina Division of Public Health, is approved as a provider of
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: nusinersen_spinraza 03/2017 10/2018 10/2019 10/2018 Description of Procedure or Service Spinal muscular atrophy
More informationNewborn Screening: Train the Trainer PPT Questions
Newborn Screening: Train the Trainer PPT Questions Bloodspot Screening Purpose 1. How many possible hidden disorders does the Oklahoma Newborn Screening Program screen for? A. >10 B. >20 C. >30 D. >40
More informationNewborn Screening and Studies of Lysosomal Storage Diseases in CFOH
Newborn Screening and Studies of Lysosomal Storage Diseases in CFOH Chinese Foundation of Health National Yang-Ming University Director: Dr. Chuan-Chi Chiang Speaker: Hsuan-Chieh Liao (Joyce) 1 Newborn
More informationEvidence-Based Update: Using Glucose Gel to Treat Neonatal Hypoglycemia
Neonatal Nursing Education Brief: Evidence-Based Update: Using Glucose Gel to Treat Neonatal Hypoglycemia http://www.seattlechildrens.org/healthcare-professionals/education/continuing-medicalnursing-education/neonatal-nursing-education-briefs/
More informationSequencing in Newborn Screening Introduction and Background
Sequencing in Newborn Screening Introduction and Background Suzanne Cordovado, PhD Newborn Screening and Molecular Biology Branch Division of Laboratory Sciences Centers for Disease Control and Prevention
More informationThe Many Lives of the Newborn Screening Dried Blood Spot (the LIFE CYCLE of a Blood Spot)
The Many Lives of the Newborn Screening Dried Blood Spot (the LIFE CYCLE of a Blood Spot) Piero Rinaldo, MD, PhD Professor of Laboratory Medicine T. Denny Sanford Professor of Pediatrics Mayo Clinic College
More informationAdult-onset Krabbe disease in two generations of a Chinese family
Original Article on Translational Neurodegeneration Page 1 of 6 Adult-onset Krabbe disease in two generations of a Chinese family Tongxia Zhang 1, Chuanzhu Yan 1,2,3, Kunqian Ji 1, Pengfei Lin 1, Lingyi
More informationASBMT and Marrow Transplantation
Biol Blood Marrow Transplant 19 (2013) 616e624 Neurodevelopmental Outcomes of Umbilical Cord Blood Transplantation in Metachromatic Leukodystrophy Holly R. Martin 1,y, Michele D. Poe 2,y, James M. Provenzale
More informationTEST INFORMATION Test: CarrierMap GEN (Genotyping) Panel: CarrierMap Expanded Diseases Tested: 311 Genes Tested: 299 Mutations Tested: 2647
Ordering Practice Jane Smith John Smith Practice Code: 675 Miller MD 374 Broadway New York, NY 10000 Physician: Dr. Frank Miller Report Generated: 2016-02-03 DOB: 1973-02-19 Gender: Female Ethnicity: European
More informationCYP21A2 Mutations Found in Congenital Adrenal Hyperplasia Patients in the California Population
CYP21A2 Mutations Found in Congenital Adrenal Hyperplasia Patients in the California Population Christopher N. Greene, Ph.D. Newborn Screening and Molecular Biology Branch National Center for Environmental
More informationYES NO UNKNOWN PENETRANCE ACTIONABILITY SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES (Proceed to Stage II) YES ( 1 of above)
Stage I: Rule-Out Dashboard GENE/GENE PANEL: ATP7B DISORDER: Wilson Disease HGNC ID: 870 OMIM ID: 277900 ACTIONABILITY 1. Is there a qualifying resource, such as a practice guideline or systematic review,
More informationClinical Approach to Diagnosis of Lysosomal Storage Diseases
Clinical Approach to Diagnosis of Lysosomal Storage Diseases M. Rohrbach, MD, PhD FMH Pädiatrie und FMH Medizinische Genetik Abteilung Stoffwechsel Universitätskinderklinik Zürich Lysosomal storage disorders
More informationCord blood and bone marrow transplantation in inherited metabolic diseases: scientific basis, current status and future directions
review Cord blood and bone marrow transplantation in inherited metabolic diseases: scientific basis, current status and future directions Vinod K. Prasad and Joanne Kurtzberg The Pediatric Blood and Marrow
More informationLeukodystrophies have been defined as inherited,
Transplant Outcomes in Leukodystrophies Paul J. Orchard and Jakub Tolar Hematopoietic stem cell transplantation (HSCT) has been used for three decades as therapy for lysosomal storage diseases. Stable
More informationNewborn bloodspot results: predictive value of screen positive test for thalassaemia major
Original Article Newborn bloodspot results: predictive value of screen positive test for thalassaemia major J Med Screen 20(4) 183 187! The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalspermissions.nav
More informationReport of the 2011 LSD World Symposium 15 th to 18 th February Introduction
Report of the 2011 LSD World Symposium 15 th to 18 th February 2011 Introduction This is the report of the 2011 LSD World Symposium. Save Babies Through Screening Foundation in the USA kindly sponsored
More informationEVOLUTIONARY GENETICS LAB PROBLEMS
ANTHR 1-L: Bio Anthro Lab Name: EVOLUTIONARY GENETICS LAB PROBLEMS 1. In Likis, a type of monkey (hypothetical), a single dominant allele determines whether or not a Liki is spotted (S) or not (nonspotted
More informationmyelin in the CNS Multiple axons are oligodendrocyte
Pathologic classification of white matter disorders d Demyelinating - loss of normal myelin autoimmune/inflammatory component Dysmyelinating - loss of chemically abnormal myelin Hypomyelinating - paucity
More informationSMA IS A SEVERE NEUROLOGICAL DISORDER [1]
SMA OVERVIEW SMA IS A SEVERE NEUROLOGICAL DISORDER [1] Autosomal recessive genetic inheritance 1 in 50 people (approximately 6 million Americans) are carriers [2] 1 in 6,000 to 1 in 10,000 children born
More informationMETABOLISM OF ACYLGLYCEROLS AND SPHINGOLIPDS. Ben S. Ashok MSc.,FAGE.,PhD., Dept. of Biochemistry
METABOLISM OF ACYLGLYCEROLS AND SPHINGOLIPDS Ben S. Ashok MSc.,FAGE.,PhD., Dept. of Biochemistry STORAGE AND MEMBRANE LIPIDS STORAGE LIPIDS Mainly as triacylglycerols (triglycerides) in adipose cells Constitute
More informationClinical Policy Bulletin: Nusinersen (Spinraza)
Clinical Policy Bulletin: Nusinersen (Spinraza) Number: 0915 Policy *Pleasesee amendment forpennsylvaniamedicaidattheendofthiscpb. Note: REQUIRES PRECERTIFICATION.Footnotes for Precertification of nusinersen
More informationGeneral Guidelines for Health professionals
General Guidelines for Health professionals Page 1 Haemochromatosis Introduction Hereditary haemochromatosis (HH) now easily screened for as most symptomatic individuals are homozygous for the C282Y mutation
More informationReproductive Technology, Genetic Testing, and Gene Therapy
Michael Cummings Chapter 16 Reproductive Technology, Genetic Testing, and Gene Therapy David Reisman University of South Carolina 16.1 Infertility Is a Common Problem In the US, about 13% of all couples
More informationDisclosures. Newborn Screening for Severe Combined Immune Deficiency Syndromes (SCIDS): Why; why now? Learning objectives.
Newborn Screening for Severe Combined Immune Deficiency Syndromes (SCIDS): Why; why now? Anthony J. Infante, MD, PhD Professor, Pediatrics and Microbiology & Immunology Chief, Division of Immunology &
More informationPopulation Screening for Fragile X Syndrome
Population Screening for Fragile X Syndrome FLORA TASSONE PH.D. DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR MEDICINE AND MIND INSTITUTE UC DAVIS, CALIFORNIA USA Molecular Pathology: Principles in Clinical
More informationShould Universal Carrier Screening be Universal?
Should Universal Carrier Screening be Universal? Disclosures Research funding from Natera Mary E Norton MD University of California, San Francisco Antepartum and Intrapartum Management June 15, 2017 Burden
More informationPedigree Analysis Why do Pedigrees? Goals of Pedigree Analysis Basic Symbols More Symbols Y-Linked Inheritance
Pedigree Analysis Why do Pedigrees? Punnett squares and chi-square tests work well for organisms that have large numbers of offspring and controlled mating, but humans are quite different: Small families.
More informationTIMELINESS OF NEWBORN SCREENING: RECOMMENDATIONS FROM ADVISORY COMMITTEE ON HERITABLE DISORDERS IN NEWBORNS AND CHILDREN
TIMELINESS OF NEWBORN SCREENING: RECOMMENDATIONS FROM ADVISORY COMMITTEE ON HERITABLE DISORDERS IN NEWBORNS AND CHILDREN Susan Tanksley, PhD May 19, 2015 TIMELINESS - BACKGROUND In order to effectively
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Choroideremia OMIM number for disease 303100 Disease alternative names please
More informationGloboid cell leukodystrophy (GLD, also called Krabbe s
Galactocerebrosidase-deficient oligodendrocytes maintain stable central myelin by exogenous replacement of the missing enzyme in mice Yoichi Kondo*, David A. Wenger, Vittorio Gallo, and Ian D. Duncan*
More informationModeling of early-infant brain growth using longitudinal data from diffusion tensor imaging.
Modeling of early-infant brain growth using longitudinal data from diffusion tensor imaging. Guido Gerig, Neda Sadeghi, PhD, Marcel Prastawa, Tom Fletcher, Clement Vachet Scientific Computing and Imaging
More informationThe aim of this study was to investigate the reliability
Jacqueline M. Langendonk, 1 C. E. M. van Beijsterveldt, 1 Silvia I. Brouwer, 1 Therese Stroet, 1 James J. Hudziak, 1,2 and Dorret I. Boomsma 1 1 Department of Biological Psychology,Vrije Universiteit,Amsterdam,
More informationThe 2017 Update of the Standard of Care Recommendations for Spinal Muscular Atrophy
Richard Finkel, MD Nemours Children s Hospital Orlando, FL, USA Thomas Crawford, MD Johns Hopkins Hospital Baltimore, MD, USA The 2017 Update of the Standard of Care Recommendations for Spinal Muscular
More informationHematopoietic Stem Cell Transplant in Sickle Cell Disease- An update
Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology and Stem Cell Transplant
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: London North East RGC GOSH Approved: September
More informationGene$cs: Part V. Extending Mendel APGRU5L5
Gene$cs: Part V Extending Mendel APGRU5L5 Do Now: 1. The Mother is blue, father is white. The offspring is checkered blue and white. Is this co-dominance or incomplete dominance? 2. A black cat and a white
More informationCODING REVIEW FOR ACCESS2MD PROVIDERS
CODING REVIEW FOR ACCESS2MD PROVIDERS May 27, 2015 Tricia Stanley, DNP, RN, ANP-BC, FNP-BC TYPES OF CODES CPT What was done during the visit Two Types CPT Evaluation and Management ICD Why it was done
More informationGENETICS - NOTES-
GENETICS - NOTES- Warm Up Exercise Using your previous knowledge of genetics, determine what maternal genotype would most likely yield offspring with such characteristics. Use the genotype that you came
More informationSALSA MLPA KIT P060-B2 SMA
SALSA MLPA KIT P6-B2 SMA Lot 111, 511: As compared to the previous version B1 (lot 11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). Please note that, in contrast to the
More informationInfectious Disease Update
Infectious Disease Update Karen Rose, RN BSN Communicable Disease Surveillance Nurse; Office of Epidemiology WeArePublicHealth.org twitter.com/maricopahealth facebook.com/mcdph Today s Updates: Influenza
More information6.1 Extended family screening
CHAPTER 6 CONCLUSION Cost benefit analysis of thalassemia screening programs have shown that the single years treatment for a β-thalassemia major patient was much higher than a total cost per case prevented.
More informationValencia, 05/04/ #EBMT16
Transplantation of Ex vivo Expanded Umbilical Cord Blood (NiCord ) Results in Decreased Infection Burden and Hospital Length of Stay in the First 100 Days Sarah Anand, Samantha Thomas, Terry Hyslop, Kelly
More informationNewborn Screening for Cystic Fibrosis
Newborn Screening for Cystic Fibrosis Three States Experience with IRT/IRT/DNA Marci Sontag PhD, Norm Brown, Dan Wright, Art Cowes, Rachel Lee, Susan Tanksley Colorado School of Public Health and Children
More informationArticle Preimplantation diagnosis and HLA typing for haemoglobin disorders
RBMOnline - Vol 11. No 3. 2005 362-370 Reproductive BioMedicine Online; www.rbmonline.com/article/1853 on web 20 July 2005 Article Preimplantation diagnosis and HLA typing for haemoglobin disorders Dr
More informationGenetics Review. Alleles. The Punnett Square. Genotype and Phenotype. Codominance. Incomplete Dominance
Genetics Review Alleles These two different versions of gene A create a condition known as heterozygous. Only the dominant allele (A) will be expressed. When both chromosomes have identical copies of the
More informationLearn the steps to identify pediatric muscle weakness and signs of neuromuscular disease.
Learn the steps to identify pediatric muscle weakness and signs of neuromuscular disease. Listen Observe Evaluate Test Refer Guide for primary care providers includes: Surveillance Aid: Assessing Weakness
More informationWelcome to this four part series focused on epidemiologic and biostatistical methods related to disease screening. In this first segment, we will
Welcome to this four part series focused on epidemiologic and biostatistical methods related to disease screening. In this first segment, we will discuss essential components for effective screening programs.
More informationLetter of Medical Necessity The Use of SPINRAZA (nusinersen) for Spinal Muscular Atrophy
TEMPLATE Letter of Medical Necessity The Use of SPINRAZA (nusinersen) for Spinal Muscular Atrophy Date: [Insert Name of Medical Director] RE: Patient Name [ ] [Insurance Company] Policy Number [ ] [Address]
More informationCook Children s HI Center. Paul Thornton Medical Director Cook Children s Hyperinsulinism Center
Cook Children s HI Center Paul Thornton Medical Director Cook Children s Hyperinsulinism Center Formed in Oct 2010 Cook Children s HI Center Mission: To provide excellence in medical care to patients with
More information